The 2016 China Pharmaceutical R & D and Innovation Summit launched

China's pharmaceutical industry is a part of the world, and how many seats in the world's pharmaceutical market are reserved for China? For the pharmaceutical industry, to enhance the international competitiveness of China's pharmaceutical industry through R & D innovation and change the mode of economic development is not only the ultimate way for enterprises, but also the only way for China's pharmaceutical industry to go to the world In recent years, R & D innovation has been promoted to the national strategy With the increasing upsurge of R & D innovation, enterprises' understanding of innovation has changed from staying on the surface to going deep into the reality, and the Chinese pharmaceutical industry has gradually shifted from generic drugs to generic innovation Although China's pharmaceutical research and development occasionally bears fruits of innovation, it has not yet entered a substantial stage, and China's pharmaceutical industry urgently needs strength to further promote its research and development innovation From September 24 to 25, 2016, under the guidance of China Pharmaceutical University, research center for the development of contemporary Chinese medicine, Chongqing Economic and Information Technology Commission, hosted by the elite club of pharmaceutical intelligence and hosted by the website of pharmaceutical intelligence, the 2016 China Pharmaceutical R & D Innovation Summit and the conference of the top 100 research and development strength of pharmaceutical enterprises was officially launched Nearly 20 experts focused on "medical reform policy, natural medicine and clinical research" 12 reports, 1 high-end dialogue and 1 closed door Council were held on drug patent protection, FDA drug approval and clinical experiment, attracting nearly 400 enterprises and enterprise representatives At the meeting, the "2016 ranking of China's pharmaceutical R & D strength" was released, and nearly 100 enterprises represented by Hengrui, Zhengda Tianqing and Fosun won on-site awards and awarded medals Under the leadership of China's pharmaceutical giants, the innovation trend of China's pharmaceutical industry is bound to start a prairie fire and strive to compete with the world as soon as possible The meeting was popular In addition, Yu Mingde, former president of China Pharmaceutical Enterprise Management Association and honorary president of China Pharmaceutical Enterprise Management Association, Yang Liqiong, deputy director of Chongqing Economic and Information Technology Committee and executive deputy director of Chongqing pharmaceutical industry development office, Lu Jing, former vice president of China traditional Chinese medicine newspaper, member of the standing Committee and vice president of Tongnan District People's Government of Chongqing, and blue book of China Medical Reform issued by the Academy of Social Sciences Professor Fang Zhiwu, editor in chief and former member of the medical reform expert committee of the State Council, Professor of China Pharmaceutical University and member of the expert committee of the drug R & D ranking board Chen Shu attended the summit With the help of government leaders, Chongqing, China, is at the forefront of the country This summit is a grand occasion, with nearly 40 leading experts as the platform Yang Liqiong, deputy director of Chongqing Economic and Information Technology Commission and executive deputy director of Chongqing pharmaceutical industry development office, delivered a speech on the spot She said that innovation has become a national development strategy, and Chongqing's innovation and development are in a state of flux In recent years, great changes have been made "2016 China Pharmaceutical R & D Innovation Summit" is in line with the development program of the country and the city Whether it is for Chongqing or the national pharmaceutical industry, it is an innovation in itself In addition, director Yang encouraged major pharmaceutical companies to seize the highlands of Chongqing and strive to become bigger and stronger in this area Yang Liqiong, deputy director of Chongqing Economic and Information Technology Commission and executive deputy director of Chongqing pharmaceutical industry development office, delivered a speech at the scene Zhang Yilong, chairman of Chongqing pharmaceutical industry association, delivered a speech at the meeting Shi Yuanping, founder and chairman of yaozhi.com, delivered a welcome speech The expert presented 18 kinds of martial arts samples to the heart of the enterprise At the summit, more than 10 experts and professors broke down every point of the R & D link one by one Yu Mingde, the former president of China Pharmaceutical Enterprise Management Association and honorary president of China Pharmaceutical Enterprise Management Association, published the development situation, policies and suggestions of the pharmaceutical industry, Fang Zhiwu, the editor in chief of China Medical Reform Blue Book of Chinese Academy of Social Sciences and former member of the medical reform expert committee of the State Council, published China medical reform The new trend and its impact on the pharmaceutical industry "is based on the policy of the pharmaceutical industry, on the basis of top-level design, combined with the enterprise's own situation to improve and prospect Experts at the summit demonstrated that natural drugs are an important source of new drugs, and how to make a breakthrough is also a focus of innovation Professor He Yun, expert of the national thousand talents program, director of the center for innovative drug research of Chongqing University, and doctoral supervisor, made an exclusive disclosure on the global trend and hot spots of natural drug research Hou Yu, Professor of Hebei University of science and technology and President of Kangzhou pharmaceutical big data development and Application Research Institute, made a point-to-point analysis on the construction and methods of drug patent protection; Gong Zhaolong, the former senior drug review expert of FDA and CEO of mindI Pharmaceutical Technology Co., Ltd., explored the new trend of FDA drug approval on the spot, providing reference for relevant domestic review and approval agencies and drugs entering the international market, and shortening the transformation of enterprises Innovation path In addition, Professor Zhong Weide, the new generation urology expert and the chief physician of Guangzhou first people's Hospital, and Wang Shumin, the deputy chief physician of clinical experimental organization of Tongren Hospital Affiliated to Capital Medical University, discussed the clinical trial and clinical data verification of the enterprise, and cleared the obstacles in the clinical aspect of the enterprise Li Tianquan, the co-founder and chairman of the elite club of pharmaceutical intelligence, gave a wonderful speech on the application of big data in pharmaceutical research and development at the conference, combining big data with medicine, which aroused the keen attention of people in the pharmaceutical industry to big data The wonderful and frequent reports of all kinds of celebrities won the applause of the whole hall For enterprises, this kind of experts who can focus the attention of pharmaceutical companies for decades have been released together, and the whole process of R & D innovation has been breached, which is undoubtedly an effective measure to solve the transformation and upgrading of enterprises It's no exaggeration to say that this summit is no less than an earthquake for the industry reform It's not only a simple speech in the literal sense, but also a selective choice in the selection of guests and the content of the report It also makes the R & D strength of more than 5000 pharmaceutical enterprises in China fully disclosed The top 100 or top 50 R & D rookies are calculated by the scores of drug acceptance in 2015 (from January 1 to December 31, 2015), drug approval in 2015 (from January 1 to December 31, 2015), drug R & D fund investment in 2015 and corporate brand vote (brand vote is only included in the general list) At the award ceremony of 2016 China Pharmaceutical R & D strength ranking, the ranking was of great significance As soon as it was born, it focused on the attention of pharmaceutical giants in the industry Jiangsu Hengrui, Zhengda Tianqing, Fosun and other famous enterprises came to take part in and receive awards Their arrival not only adds luster to this meeting, but also strengthens the call of pharmaceutical enterprises for R & D and innovation Under the leadership of the industry's top executives, the brilliant future of R & D in China's pharmaceutical industry will not be too far away, and the "made in China" of innovative drugs will not wait too long Original statement: This article is the original manuscript of yaozhi.com, welcome to reprint, reprint please indicate the source, thank you!